Multiple Sclerosis

1. Structural Plasticity and Regeneration in the Adult Brain and Spinal Cord 2. Mechanisms of Demyelination in MS 3. Axonal Loss in MS 4. Axonal Injury in Early Chronic MS Lesions 5. Neuronal Control of the Immune Response in the Central Nervous System 6. Oligodendrocyte Susceptibility to Immune Mediated Injury 7. Effects of BDNF and NGF on Cytokine Expression in Immune Cells 8. Interleukin-6 Expression in Early MS Lesions 9. Remyelination in MS: Potential Use of Transplanted Glia 10. Oligodendrocyte Progenitors 11. Growth Factors, Lesion Repair and Myelin Regeneration 12. Magnetization Transfer Imaging 13. Black Holes, Clinicopathological Correlations; MRI Markers for Axonal Loss 14. Spectroscopy 15. Improvement of Magnetization Transfer Ratio in New Gadolinium Enhancing Lesions Detected Before and During Therapy with Interferon Beta-la 16. The Effect of IFN Beta-lb on the Evolution of New Enhancing Lesions to Hypointense T1 Lesions in Secondary Progressive MS 17. One Year Serial Clinical and MRI Study of Primary Progressive MS 18. Quantification of Tl and T2 Lesion Load 19. Measurement of Atrophy 20. Post-Processing of MRI-Data 21. Functional Imaging CSF Markers of Tissue Destruction and Repair 22. Peripheral Blood Markers 23. Urine Myelin Basic Protein-Like Material in MS 24. The Role of Neurophysiology Pathophysiology of Fatigue Assessment and Treatment Options in MS Fatigue 25. Novel Potential Autoantigens 26. Degeneracy of Antigen Recognition by T-Cells 27. T-Cell Apoptosis in the Nervous System 28. Why Did the TNF-Strategy Not Work? 29. IL-12: Immunological Staging of MS and a Measure of Response to Therapy 30. Interferon-Beta Inhibits Inducible IL-12 Production in Human Peripheral Blood Mononuclear Cells Through an IL-10-Dependent Mechanism 31. Matrix Metalloproteinase Inhibitors: Current and Novel Drugs for MS Therapy 32. T-Cell Vaccination, T-Cell Receptor Peptides and Antigen-Driven Immunotherapies 33. Altered Peptide Ligands and Immune-Deviation 34. Critical Perspective on Selective Immunointerventions 35. Update on Steroids 36. Plasma Exchange Reverses Severe Neurological Disability in Corticosteroid-Refractory Attacks of Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System 37. Intensive Immunosuppression: Toxicity vs Efficacy 38. Is There a Role of Intensive Immunosuppression? 39. Autologous Stem Cell Transplantation 40. Mitoxantrone in Progressive MS: Clinical Results and Three-Year Follow-Up of the MIMS Trial 41. A Double-Blind, Dose Escalation Study of Safety, Biological and Preliminary Clinical Activity of AG284 in Patients with Secondary Progressive MS 42. Double-Blind, Placebo Controlled, Multicenter Study Evaluating Safety, Tolerability and Effect of the Altered Peptide Ligand M5P771 on MRI Activity in Relapsing- Remitting MS 43. The European Study on Enzyme Therapy in MS 44. The Effects of IFN Beta-1a in Patients with Acute Neurological Syndromes Suggesti ve of MS 45. Intravenous Immunoglobulin in Childbirth-Related Exacerbations of MS Therapy-Induced and Anti-Interferon Beta Antibodies Against Interferon Beta-a and Interferon Beta-lb in Patients with MS 46. Longitudinal Prospective Investigations of the Evolution of Neutralizing Antibodies and Treatment Effects in MS Patients Treated Long-Term with Interferon Beta-lb